| Literature DB >> 35050073 |
Lyanne Rodríguez1, Diego Mendez1, Hector Montecino1, Basilio Carrasco2, Barbara Arevalo2, Iván Palomo1, Eduardo Fuentes1.
Abstract
In terms of safe and healthy food, beans play a relevant role. This crop belongs to the species of Phaseolusvulgaris L., being the most consumed legume worldwide, both for poor and developed countries, the latter seek to direct their diet to healthy feeding, mainly low in fat. Phaseolus vulgaris L. stands out in this area-an important source of protein, vitamins, essential minerals, soluble fiber, starch, phytochemicals, and low in fat from foods. This species has been attributed many beneficial properties for health; it has effects on the circulatory system, immune system, digestive system, among others. It has been suggested that Phaseolus vulgaris L. has a relevant role in the prevention of cardiovascular events, the main cause of mortality and morbidity worldwide. Conversely, the decrease in the consumption of this legume has been related to an increase in the prevalence of cardiovascular diseases. This review will allow us to relate the nutritional level of this species with cardiovascular events, based on the correlation of the main bioactive compounds and their role as cardiovascular protectors, in addition to revealing the main mechanisms that explain the cardioprotective effects regulated by the bioactive components.Entities:
Keywords: Phaseolus vulgaris L.; beans; bioactive compounds; cardioprotective; cardiovascular diseases
Year: 2022 PMID: 35050073 PMCID: PMC8779353 DOI: 10.3390/plants11020186
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Compounds identified in Phaseolus vulgaris L. A7G: apigenin-7-glucoside [51], ADA: aldaric acid [51], B1: thiamine [33], B6: vitamin B6 [33], Bcar: β-carotene [52], CA: kaphtharic acid [53], CAA: caffeic acid [51], CAT: catechin [52], CGA: chlorogenic acid [54], CIN: cinnamic acid [51], Cou: coumetrol [51], CouA: coumaric acid [51], CuA: p-coumaryl aldaric acid [55], Cy3G: cyanidin-3-glucoside [52], DAI: daidzein [51], DEL: delphinidin [51], EPI: epicatechin [56], FAA: feruloyl aldaric acid [51], FAD: folic acid [33], FCA: ferulic acid [51], FMN: formononetin [51], GAL: gallic acid [51], GEN: genistein [51], GLA: syringic acid [54], GLE: glycitein [51], HA: synapic acid [51], HBA: hydroxybenzoic acid [51], HST: hesperetin [51], K3G: kaempferol-3-glucoside [57], K3GX: kaempferol 3-glucosylxilosido [57], K3X: kaempferol 3-xylosylglucoside [57], L7G: luteolin-7-glycoside [51], Leu: leucine [58], LLA: linolenic acid [26], Lys: lysine [58], Lys: lysine [58], Mal: malvidin [51], NAR: naringenin [51], NIA: niacin [33], OLA: oleic acid [59], omega-3: omega-3 [54], omega-3: omega-3 [54], omega-6: omega-6 [54], P35D: pelargonidin 3,5-diglycoside [51], P3M: pelargonium-3-(6″-malonyl)glucoside [51], PAL: Palmitic acid [59], PCA: Protocatechuic acid [51], PCA: Palmitic acid [56], Pg3G: Pelargonidin-3-glucoside [52], Phe: phenylalanine [58], Pt: petunidine [51], RAF: raffinose [60], RF: riboflavin [33], SAA: sinapil aldaric acid [55], SRA: syringic acid [51], ST: starch [54], Sta: Stachyose [60], TAX: taxifolin [51], TFA: transferulic acid [51], Toc: tocopherol [52], Tyr: tyrosine [58], VAN: vanilic acid [51], VER: verbascosa [60]. Source: created by the authors.
Cardioprotective studies of bioactive compounds from Phaseolus vulgaris L.
| Compound | Classification | Mechanisms |
|---|---|---|
| Coumaric acid | Phenolic acid | Reduces ADP-induced platelet aggregation in vitro. Modifies platelet function, measured with PFA-100 (500 and 1 µM). |
| Reduces apoptosis in vivo in rats with isoproterenol-induced myocardial infarction by inhibiting oxidative stress (2.4 and 8 mg/kg). | ||
| Inhibits in vitro TRAP-induced surface P-selectin expression (100 μmol/L) [ | ||
| Inhibits in vivo LDL oxidation and decreases MDA production, causing a decrease in atherosclerosis (100 mg/kg) [ | ||
| Protects the heart in vivo against DOX-induced oxidative stress (100 mg/kg) [ | ||
| Chlorogenic acid | Phenolic acid | Inhibits in vitro platelet secretion and aggregation induced by ADP, collagen, AA, and TRAP-6. Decreases platelet adhesion, aggregation, and platelet–leukocyte interactions under flow conditions. Inhibits platelet inflammatory mediators (P-selectin, sCD40L, CCL5, and IL-1β) and increases intra-platelet cAMP levels by activation of PKA (0.1 to 1 mmol/L). |
| Inhibits collagen-induced platelet aggregation and suppresses TxA2 production, associated with COX-1 inhibition in platelet microsomes that have activity on cytochrome c reductase. Increases the formation of cAMP and cGMP and intracellular Ca2+ (10, 30, and 50 mmol/L). | ||
| Ferulic acid | Phenolic acid | Inhibits in vitro the expression of P-selectin on the surface induced by TRAP (100 μmol/L). Inhibits platelet aggregation induced with collagen 3.5 μg/mL (100 μmol/L) [ |
| Inhibits in vitro platelet aggregation stimulated with ADP 8 μmol/L and collagen 1.5 μg/mL (0.5 mmol/L) [ | ||
| Protects in vivo death produced by pulmonary thrombosis and prolongs tail bleeding time in mice and rats (20, 40, and 80 mg/kg for mice, or 10, 20, and 40 mg/kg for rats). | ||
| Synapic acid | Phenolic acid | Inhibits in vitro platelet aggregation and coagulation with antithrombotic effect (0.25 mg/mL, IC50: 1.03 mM) [ |
| Protocatechic acid | Phenolic acid | Decreases in vitro SIPA and attenuates platelet activation, intracellular Ca2+ mobilization, granule secretion, and adhesion receptor expression (10–25 µM). |
| Reduces myocardial infarction size, serum TNF-α levels, and platelet aggregation in vitro. Inhibits apoptosis and caspase-3 expression and positively regulates phosphorylated Akt expression in cardiomyocytes subjected to injury by | ||
| Inhibits platelet apoptosis induced by decreased dissipation of mitochondrial membrane potential, activation of caspase-9 and caspase-3, and decreased exposure to PS. Modulates the distributions of Bax, Bcl-xL, and cytochrome c mediated by H2O2 in mitochondria and cytochrome. It decreases ROS generation and intracellular Ca2+ concentration, caspase-3 signaling and activation, and PS exposure (0.5 or 1 µM). | ||
| Syringic acid | Phenolic acid | Inhibits clotting factors, decreases the secretion of dense granules, and retraction of the clot. Regulates the downstream signaling pathway of DEP-1/PTP-1B/αIIbβ3/kinases. It decreases the expression of density-enhanced phosphatase-1 (DEP-1)/protein tyrosine phosphatase-1B (PTP1B)/αIIbβ3, as well as the phosphorylation of platelet kinases stimulated with collagen/epinephrine both in vitro and in vivo (5, 10 and 20 µg). It inhibits the secretion of granular components, clot retraction, and FeCl3-induced vascular occlusion of the carotid artery. |
| Myricerin | Flavonoid | Reduces the ability of platelets to spread on collagen and form thrombi in vitro without affecting hemostasis in vivo. Inhibits the activities of PDI and ERp5 reductase (10, 30, or 100 µM). |
| Inhibits in vitro PAF-induced platelet adhesion (IC50: 13.1 mmol/L) and internal free Ca2+ concentration. It inhibits platelet aggregation PAF 1, 2, and 4 nmol/L with IC50: 34.8, 85.7, and 118.6 mmol/L. Mechanism: antagonizes the specific binding of the PAF receptor [ | ||
| Inhibits in vivo 3.6 µg/kg cat blood platelet aggregation. Reduces platelet thrombi in vitro at a concentration of 60 nM. | ||
| Inhibits platelet aggregation. Increases the cAMP stimulated by PGI2. Inhibits lipoxygenase activity (50 µM). | ||
| Genistein | Isoflavonoid | Inhibits in vitro human platelet aggregation, serotonin secretion, and phosphorylation of protein tyrosine induced by collagen and TxA2. It slightly attenuates thrombin-induced protein tyrosine phosphorylation (100 μg/mL). |
| Inhibits in vitro dose-dependent collagen-induced platelet aggregation, NO production, and TNF-α secretion. Decreased secretion of MCP-1 induced by TNF-α in endothelial cells of the human umbilical vein (50 µM). | ||
| Inhibits platelet aggregation or the release of serotonin-induced by thrombin and Ca2+. Inhibits the COX pathway and PI3 and PI(4,5)P2 (50 µM) production. | ||
| Decreases PAF stimulation of PLC activity at baseline. Inhibits PAF-stimulated platelet aggregation. Inhibits PI3 production and reduces induced phosphorylation (0.5 mM). | ||
| Glycythein | Isoflavonoid | Inhibits proliferation and synthesis of SMC DNA induced by PDGF-BB (3–10 μmol/L). |
| Formononetin | Isoflavonoid | Inhibits ferric chloride-induced arterial thrombus formation in rats and ADP- and thrombin-stimulated platelet aggregation in rats. Prolongs bleeding time and aPTT in mice |
| Inhibits PDGF-BB-induced proliferation and migration of human VSMCs. Inhibits upregulation of cell cycle-related proteins, matrix metalloproteinase, and PDGF-BB-induced phosphorylation of AKT in VSMC (1 µM). | ||
| Increases cell migration, tube formation, and levels of PECAM-1 and VEGF and platelet endothelial cells of the human umbilical vein. Protects against cerebral ischemia and reperfusion injury in rats. Improves cerebrovascular angiogenesis in human umbilical vein endothelial cells (10 and 20 µg/mL). | ||
| Naringenin | Flavanone | Decreases kidney failure in rats and the lipid profile. Inhibits levels of inflammation markers and pro-oxidants in the kidney of rats. Moderate platelet parameters (50 mg/kg/90 days). |
| Hesperetin | Flavanone | Inhibits in vitro platelet aggregation induced with collagen 5 μg/mL and AA 0.5 μmol/L (IC50: 20.5 and IC50: 69.2). Collagen-induced cytosolic Ca2+ mobilization decreases from 10 μg/mL to 20–50 μM. Inhibits collagen-stimulated serotonin secretion at IC50: 10.5 and IC50: 25.2. |
| Inhibits in vivo platelet aggregation induced with ADP and collagen (100 mg/kg) [ | ||
| Daidzein | Isoflavonoid | Inhibits in vitro dose-dependent collagen-induced platelet aggregation, NO production, and TNF-α secretion. Decreases secretion of MCP-1 induced by TNF-α in endothelial cells of the human umbilical vein (50 µM). |
| Inhibits proliferation and synthesis of SMC DNA induced by PDGF-BB (3–10 μmol/L). | ||
| Catechin | Flavonol | Inhibits collagen-induced platelet aggregation and platelet adhesion to collagen (50–100 µmol/L). |
| Inhibits platelet aggregation induced by AA, ADP, and Mepinephrine (200 µg/mL). Decreases MDA production from AA-stimulated platelets (20–200 µg/mL). | ||
| Ex vivo platelet function improvement in iron-loaded rats, associated with impaired antioxidant defense, including free radical-induced hemolysis (10 mg/kg). | ||
| Kaempferol-3-glucoside | Flavonol | Inhibits in vitro platelet aggregation induced with 100 μM AA and 10 μg/mL collagen to 22 μM. |
| Inhibits in vitro platelet aggregation induced by AA 100 μM and collagen 10 μg/mL to 100 μg/mL [ | ||
| Inhibits in vitro of platelet aggregation induced with AA 150 μM at IC50: 24 μM [ | ||
| Luteolin-7 glycoside | Flavone | Inhibits the proliferation of CMLV induced by PDGF-BB 1/2) and DNA synthesis in CMLV (50 uM). |
| Coumarin | Benzopyrone | Inhibits platelet aggregation and release of ATP from rabbit platelets induced by AA, collagen, ADP, PAF) and U46619 (analogous to TxA2). Inhibits degradation of phosphoinositide caused by collagen and PAF (200 uM). |
| Inhibits platelet aggregation (25.75 ± 4.12%). Shows the percentage of binding with GPIIb/IIIa receptor (0.5 and 2 mM) [ | ||
| Inhibits AA-induced platelet aggregation. It does not interfere with the function of TxA2 synthase, but they were competitive antagonists of TxA2 receptors and inhibited COX-1 (50 µM). | ||
| Starch | Sugar | Reduces availability of the fibrinogen receptor. |
| Tocopherol | Tocopherol | Inhibits in vitro the aggregation induced by ADP, AA, PMA. Inhibits in vivo PMA-induced stimulation of PKC (400 to 1200 µL/d). |
| Inhibits platelet aggregation induced by ADP and PMA. Increases NO release, ecNOS activation, and platelet protein SOD content. Decreases the activation of PKC (45 mg of α-tocopherol equivalents). | ||
| Omega-3 and 6 | Fatty acid | Decreases in vivo reactivity of P2Y12 by 22.2%. Inhibits ADP-induced platelet aggregation. |
| Reduces in vivo thrombin formation and oxidative stress and favorably alters the properties of the fibrin clot (1 g/day of PUFA n-3) [ | ||
| Increases the total surface load of platelets and attenuates platelet activation (1 to 8 g/day) [ | ||
| Delphinidin | Anthocyanin | Inhibits in vitro the secretion of alpha granules: PF4, β-TG, P-selectin, TGF-β1, RANTES, ATP, and serotonin and CD63 induced with thrombin 0.5 U/mL. |
| Inhibits platelet aggregation induced with 5 µM ADP, 2 µg/mL collagen, and 100 µM TRAP. | ||
| Cyanidin-3-O-glucoside | Anthocyanin | Inhibits in vitro the secretion of alpha granules: PF4, β-TG, P-selectin, TGF-β1, RANTES, ATP, and serotonin and CD63 induced with thrombin 0.5 U/mL. |
| Inhibits platelet aggregation induced with 2.5 µg/mL collagen, 0.1 U/mL thrombin, and 100 µM TRAP-6. | ||
| Pelargonidine-3-O-glucoside | Anthocyanin | Prolongs aPTT and PT. Inhibits thrombin and FXa activity and production in human umbilical vein endothelial cells. Inhibits thrombin-catalyzed polymerization of fibrin and platelet aggregation and anticoagulant effect elicited in mice (10 µM) [ |
| Inhibits in vitro the secretion of alpha granules: PF4, β-TG, P-selectin, TGF-β1, RANTES, ATP, and serotonin and CD63 induced with thrombin 0.5 U/mL. |
Abbreviations: AA: arachidonic acid, ADP: adenosine diphosphate, Akt: protein kinase B, aPTT: activated partial thromboplastin time, ATP: adenosine triphosphate, cAMP: cyclic adenosine monophosphate, CCL5: type 5 receptor chemokine, CD63: gene encoded by the symbol CD63, VSMC: vascular smooth muscle cells, COX-1: cyclooxygenase 1, DOX: doxorubicin, ecNOS: constitutive endothelial nitric oxide synthase, ERp5 reductase: endoplasmic reticulum protein 5, PLA: phospholipases A2, VWF: factor de von Willebrand, FXa: tissue factor, cGMP: cyclic guanosine monophosphate, GPIb: glycoprotein, IL-1β: interleukin-1-beta, IP3: inositol triphosphate, LDH: lactate dehydrogenase, MAPK: mitogen-activated protein kinase, MCP-1: monocyte chemoattractant protein 1, MDA: malondialdehyde, NO: nitrogen oxide, PAF: platelet activating factor, PDE: phosphodiesterase, PDGF: platelet growth factor, PDI: protein disulfide isomerase, PECAM-1: molecule platelet-endothelium adhesion cells, PGI2: prostacyclin, PI(4,5)P2: phosphatidylinositol-4,5-bisphosphate, PKA: protein kinase A, PKC: protein kinase C, PLC: phospholipase, PMA: phorbol myristate acetate, PS: phosphatidylserine, PT: prothrombin time, RANTES: subfamily chemokine C, ROS: reactive oxygen species, sCD40L: differentiation groups or differentiation antigens, SMC: smooth muscular system, SOD: superoxide dismutase, TGF-β1: transforming growth factor beta-1, TNF-α: tumor necrosis factor alpha, TRAP: thrombin receptor activator for peptide 6, TxA2: thromboxane, VASP: vasodilator-activated phosphoprotein, VEGF: vascular endothelial growth factor, β-TG: ß-thromboglobulin.
Figure 2Targets studied about Phaseolus vulgaris. (a) NOS protein (PDB:ID 3NLE) [237]. (b) Porcine gastric mucosa (PDB code: 5PEP [240]. (c) Porcine pancreatic lipase (PDB code: 1 ETH) [241]. Source: adapted images according to PDB ID.
Figure 3Therapeutic targets associated with CVD. (a) Adenosine A2A receptor (PDB ID: 2YDV) [242]. (b) P2Y1 receptor (PDB ID:4XNV) [243]. (c) Thromboxane receptor TxA2 (PDB ID: 6IIU) [244]. Source: all images were obtained from MemProtMD database according to the PDB ID [247].
Figure 4Cardioprotective Effects of Phaseolus vulgaris L. Source: created by the authors.